Blood Coagulation, Fibrinolysis and Lipid Profile in Patients with Primary Hyperparathyroidism: Increased Plasma Factor VII and X Activities and D-Dimer Levels

 

 Buy Article Permissions and Reprints

Abstract

Background and Objectives: Primary hyperparathyroidism (PHPT) is associated with an increased cardiovascular mortality and morbidity rate. However, the exact role of PTH and/or calcium in the development of cardiovascular disease (CVD) is still controversial. The influence of PHPT on hemostasis is yet unknown. Therefore, the main purpose of this study was to investigate the markers of endogenous coagulation/fibrinolysis and to evaluate the relationships between these hemostatic parameters, serum lipid profile and serum calcium and PTH in patients with PHPT.

Design and Methods: Twenty-three patients with PHPT and 20 age-matched healthy controls were included in the study. Fibrinogen, factors V, VII, VIII, IX and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1), as well as common lipoprotein variables, were measured. The relationships between biochemical parameters and these hemostatic parameters were examinated.

Results: Compared with the control subjects, platelet count, FVII, FX activities, and D-Dimer levels were significantly increased in patients with PHPT (p<0.001, p<0.05, p<0.001, and p<0.05, respectively). Among the lipids, the levels of TC, TG and LDL-C were significantly increased in patients with PHPT (p<0.01, p<0.001, p<0.001, respectively) than those in controls. In patients with PHPT, we showed a positive correlation between urinary phosphorus excretion and factors VIII, IX, and X (r: 0.572, p<0.01; r: 0.543, p<0.01; r: 0.532, p<0.01, respectively). F IX activity was positively correlated with TC (r: 0.463, p<0.05) and LDL-C (r: 0.549, p<0.01) There was a positive correlation between serum ALP and PAI-1 levels (r: 0.451, p<0.05). ApoB was positively correlated with D-Dimer (r: 0.421, p<0.05). We did not find any significant correlation between iPTH and serum calcium and the hemostatic parameters that we measured.

Interpretation and Conclusions: In conclusion, we found some important differences in the hemostatic parameters between the patients with PHPT and healthy controls. Increased platelet count, F VII and FX activities and D-Dimer levels in patients with PHPT represent a potential hypercoagulable state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess mortality rate due to CVD in patients with PHPT.

References

• 1 Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease–a review.  Eur Heart J. 2004;  25 1776-1787
  CrossrefPubMedGoogle Scholar
• 2 Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism–an update.  Eur J Clin Invest. 1998;  28 271-276
  Google Scholar
• 3 Kiernan TJ, O’Flynn AM, MacDermott JH, Kearney P. Primary hyperparathyroidism and the cardiovascular system.  Int J Cardiol. 2006;  113 E89-E92
  CrossrefPubMedGoogle Scholar
• 4 Rapado A. Arterial hypertension and primary hyperparathyroidism. Incidence and follow-up after parathyroidectomy.  Am J Nephrol. 1986;  6 ((Suppl 1)) 49-50
  CrossrefPubMedGoogle Scholar
• 5 Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy.  Clin Endocrinol (Oxf). 1999;  50 321-328
  Google Scholar
• 6 Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up.  J Clin Endocrinol Metab. 1997;  82 106-112
  CrossrefPubMedGoogle Scholar
• 7 Baykan M, Erem C, Erdogan T, Hacihasanoglu A, Gedikli O, Kiris A, Kucukosmanoglu M, Ersoz HO, Celik S. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism.  Int J Cardiovasc Imaging. 2007;  23 323-328
  CrossrefPubMedGoogle Scholar
• 8 Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH, Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism.  Am J Hypertens. 2000;  13 759-764
  CrossrefPubMedGoogle Scholar
• 9 Chadwick DR, Harrison BJ, Chan P, Chong L, Peachell P. Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle.  Br J Surg. 2000;  87 1529-1533
  CrossrefPubMedGoogle Scholar
• 10 Lind L, Ljunghall S. Serum calcium and the ECG in patients with primary hyperparathyroidism.  J Electrocardiol. 1994;  27 99-103
  CrossrefPubMedGoogle Scholar
• 11 Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism.  Diabet Med. 2002;  19 958-961
  CrossrefPubMedGoogle Scholar
• 12 Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years.  Clin Endocrinol (Oxf). 2002;  56 253-260
  CrossrefPubMedGoogle Scholar
• 13 Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism.  Ann Intern Med. 1994;  121 745-749
  CrossrefPubMedGoogle Scholar
• 14 Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism.  Clin Endocrinol (Oxf). 2001;  54 805-811
  CrossrefPubMedGoogle Scholar
• 15 Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O’Fallon WM, Melton LJ. Survival after the diagnosis of hyperparathyroidism: a population-based study.  Am J Med. 1998;  104 115-122
  CrossrefPubMedGoogle Scholar
• 16 Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study.  Eur J Cardiovasc Prev Rehabil. 2004;  11 69-74
  CrossrefPubMedGoogle Scholar
• 17 Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F, Lumachi F. Ultrasound evaluation of carotide artery in primary hyperparathyroidism.  J Clin Endocrinol Metab. 2003;  88 2096-2099
  CrossrefPubMedGoogle Scholar
• 18 Lumachi E, Ermani M, Luisetto G, Nardi A, Basso SMM, Camozzi V, Favia G. Relationship between serum parathyroid hormone, serum calcium and arterial blood pressure in patients with primary hyperparathyroidism: results of a multivariate analysis.  Eur J Endocrinol. 2002;  146 643-647
  CrossrefPubMedGoogle Scholar
• 19 Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study.  Am J Epidemiol. 2006;  163 334-341
  CrossrefPubMedGoogle Scholar
• 20 Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease.  Vascul Pharmacol. 2002;  39 109-112
  CrossrefPubMedGoogle Scholar
• 21 Fibrinogen Studies Collaboration. . Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease.  Eur J Cardiovasc Prev Rehabil. 2004;  11 9-17
  CrossrefPubMedGoogle Scholar
• 22 Danesh J, Whincup P, Walker M. et al . Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.  Circulation. 2001;  103 2323-2327
  CrossrefPubMedGoogle Scholar
• 23 Danesh J, Wheeler JG, Hirschfield GM. et al . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.  N Engl J Med. 2004;  350 1387-1397
  CrossrefPubMedGoogle Scholar
• 24 Lowe GD, Danesh J, Lewington S. et al . Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis.  Eur Heart J. 2004;  25 252-259
  CrossrefPubMedGoogle Scholar
• 25 Hueper W. Metastatic calcifications in the organs of the dog after injections of parathyroid extract.  Arch Pathol. 1927;  3 14-25
  PubMedGoogle Scholar
• 26 Hilgard P, Hohage R, Schmitt W, Kohle W. Microangiopathic haemolytic anaemia associated with hypercalcaemia in an experimental rat tumour.  Br J Haematol. 1973;  24 245-254
  CrossrefPubMedGoogle Scholar
• 27 Hilgard P. Experimental hypercalcaemia and whole blood clotting.  J Clin Pathol. 1973;  26 616-619
  CrossrefPubMedGoogle Scholar
• 28 Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E, Mecca G, Gaetano G de. Parathyroid hormone inhibits human platelet function.  Lancet. 1981;  2 1321-1323
  PubMedGoogle Scholar
• 29 Leithner C, Kovarik J, Sinzinger H, Woloszczuk W. Parathyroid hormone does not inhibit platelet aggregation.  Lancet. 1984;  1 367-368
  PubMedGoogle Scholar
• 30 Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia.  Haematologica. 1997;  82 96-100
  PubMedGoogle Scholar
• 31 Silverberg SJ, Bilezikian JP. Cytokines in primary hyperparathyroidism–factors that matter.  J Clin Endocrinol Metab. 1996;  81 3448-3449
  CrossrefPubMedGoogle Scholar
• 32 Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.  Blood. 2001;  98 2720-2725
  CrossrefPubMedGoogle Scholar
• 33 Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events.  Arterioscler Thromb Vasc Biol. 2005;  25 2043-2053
  CrossrefPubMedGoogle Scholar
• 34 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR. et al . Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.  Lancet. 1986;  2 533-537
  PubMedGoogle Scholar
• 35 Junker R, Heinrich J, Schulte H, Loo J van de, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men.  Arterioscler Thromb Vasc Biol. 1997;  17 1539-1544
  CrossrefPubMedGoogle Scholar
• 36 Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity.  Atherosclerosis. 1990;  85 169-173
  CrossrefPubMedGoogle Scholar
• 37 Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events.  QJM. 1994;  87 403-406
  PubMedGoogle Scholar
• 38 Heinrich J, Balleisen L, Schulte H, Assmann G, Loo J van de. Fibrinogen and factor VII in the prediction of coronary risk Results from the PROCAM study in healthy men.  Arterioscler Thromb. 1994;  14 54-59
  CrossrefPubMedGoogle Scholar
• 39 Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.  Arterioscler Thromb. 1993;  13 1829-1836
  CrossrefPubMedGoogle Scholar
• 40 Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris.  Am J Med. 1992;  93 651-657
  CrossrefPubMedGoogle Scholar
• 41 Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf N. Hypertriglycerideamia and hypercoagulability.  Lancet. 1983;  1 786-790
  PubMedGoogle Scholar
• 42 Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.  Arterioscler Thromb Vasc Biol. 1996;  16 77-81
  CrossrefPubMedGoogle Scholar
• 43 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to aVII_a in hyperlipidaemia, with possible implications for ischaemic heart disease.  Br J Haematol. 1985;  59 249-258
  CrossrefPubMedGoogle Scholar
• 44 Sousa JC de, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins.  J Clin Pathol. 1988;  41 940-944
  CrossrefPubMedGoogle Scholar
• 45 Negri M, Arigliano PL, Talamini G, Carlini S, Manzato F, Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma trigylceride levels.  Atherosclerosis. 1993;  99 55-61
  CrossrefPubMedGoogle Scholar
• 46 Hoffman CJ, Lawson WE, Miller RH, Hultin MB. Correlation of vitamin K-dependent clotting factors with cholesterol and trigylcerides in healthy young adults.  Arterioscler Thromb. 1994;  14 1737-1740
  CrossrefPubMedGoogle Scholar
• 47 Okura Y, Hayashi K, Shingu T, Kuga Y, Nomura S, Kajiyama G, Nakashima Y, Keijiro S. Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism.  Coranary Artery Dis. 2003;  14 285-291
  PubMedGoogle Scholar
• 48 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells.  Proc Natl Acad Sci USA. 1992;  89 2317-2320
  CrossrefPubMedGoogle Scholar
• 49 Koo BH, Chung KH, Hwang KC, Kim DS. Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2.  FEBS Lett. 2002;  523 85-89
  CrossrefPubMedGoogle Scholar
• 50 Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Voorhees L Van, Krone RJ, Bodenheimer MM, Hochman J, Dwyer Jr EM, Arora R, Marcus FI, Watelet LF, Case RB. Thrombo-genic factors and recurrent coronary events.  Circulation. 1999;  99 2517-2522
  CrossrefPubMedGoogle Scholar
• 51 Smith EB, Thompson WD. Fibrin as a factor in atherogenesis.  Thromb Res. 1994;  73 1-19
  CrossrefPubMedGoogle Scholar
• 52 Tataru MC, Heinrich J, Junker R, Schulte H, Eckardstein A von, Assmann G, Koehler E. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction.  Eur Heart J. 1999;  20 1493-1502 , . Comment in: Eur Heart J. 1999; 20: 1443–44.
  CrossrefPubMedGoogle Scholar
• 53 Morishita E, Jokaji H, Matsuda T. Hyperlipidemia and hemostatic system.  J Atheroscler Thromb. 1995;  2 ((Suppl 1)) S36-40
  CrossrefPubMedGoogle Scholar
• 54 Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis.  Ann Intern Med. 1997;  126 638-644
  CrossrefPubMedGoogle Scholar
• 55 Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasmin activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.  Circulation. 1998;  98 2241-2247
  CrossrefPubMedGoogle Scholar
• 56 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resist-ance in metabolic disorders: the Bruneck Study.  Diabetes. 1998;  47 1643-1649
  CrossrefPubMedGoogle Scholar
• 57 Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk.  Endocr Relat Cancer. 2003;  10 309-322
  CrossrefPubMedGoogle Scholar
• 58 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report . National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health NIH Publication No. 02-5215. September 2002; 
  PubMed

Correspondence

Prof. Dr. C. EremMD, PhD 

K.T.Ü. Tıp Fakültesi

İç Hastalıkları Anabilim Dalı

61080

Trabzon

Turkey

Phone: +90/462/377 54 49

Fax: +90/462/325 22 70

Email: cihangirerem@hotmail.com

Email: cihangirerem@netscape.net